Reference
NICE. Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma Internet Document : 15 Mar 2017. Available from: URL: https://www.nice.org.uk/guidance/GID-TA10100/documents/appraisal-consultation-document
Rights and permissions
About this article
Cite this article
NICE requests more evidence on nivolumab. PharmacoEcon Outcomes News 774, 38 (2017). https://doi.org/10.1007/s40274-017-3862-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-017-3862-6